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Soluble guanylyl cyclase (sGC) is an α/β heterodimeric
protein that is activated by nitric oxide (NO), yielding
increased intracellular levels of cGMP. Evidence in the lit-
erature suggests that endogenously produced NO, as well
as NO-donors, stimulate angiogenesis by increasing
endothelial cell (EC) proliferation, migration and organi-
zation of EC into vascular networks. Moreover, NO medi-
ates many of the angiogenic actions of vascular
endothelial growth factor. Although sGC is expressed in
the endothelium, its autocrine actions have not been thor-
oughly studied. Herein, we have investigated the role of
sGC in neo-vessel formation using the chicken chorioal-
lantoic membrane (CAM) model of angiogenesis. Ini-
tially, we confirmed the presence of sGC subunits in the
CAM during the time of maximal angiogenesis. Moreover,
when cells transfected with a luciferase reporter gene
under the control of the sGC α1 promoter were placed on
the CAM, we observed that expression of this sGC subunit
was higher at day 12 than day 6 (angiogenesis reaches its
maximum at day 12 in the CAM). The existence of catalyt-
ically active sGC in the CAM was confirmed through the
increase in cGMP tissue content after exposure to a NO
donor (sodium nitroprusside). To study the role of sGC in
angiogenesis we used several pharmacological agents that
modulate cGMP levels in tissues (ODQ, a sGC inhibitor;
BAY 41-2272, an NO-independent/heme-dependent acti-
vator of sGC; and zaprinast, a phosphodiesterase V inhib-
itor). ODQ inhibited angiogenesis in a dose-dependent
manner, while BAY 41-2272 and zaprinast promoted neo-
vascularization. In line with the in vivo data, ODQ inhib-
ited VEGF-stimulated endothelial cell migration and
organization of HUVEC into tube-like structures on
matrigel. We conclude that sGC activation promotes neo-
vessel formation.
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